Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Traxion Sab De Cv Ord Shs GRPOF

Grupo Traxion SAB de CV is a Mexico-based company engaged in the transportation sector. The Company provides logistics services within eight business areas: Fright, including intermodal and multimodal services, door-to-door, national and cross-border distribution, among others; Integrated logistics, including logistics management, aerial and maritime services and custom transportation support services; Warehousing, including dedicated storage, shared warehouses, packing and value-added services, such as labeling and products assembly; Logistics systems, including software for logistics management; Passenger transportation, including transportation of personnel and students; Special services, including rental of bus and vans; Moving, including national and international moving services, and Advertising, including custom transportation services during marketing campaigns. The Company operates through a number of group companies.


PINL:GRPOF - Post by User

Post by BLACKICE909090on Jun 29, 2018 8:55pm
162 Views
Post# 28254813

Not Just Fluff

Not Just Fluff

"In 2017, Tetra completed a major safety, pharmacokinetic and pharmacodynamic study in healthy human subjects that allowed Tetra to collect significant data to support its marketing applications. A similar clinical development program was launched with cannabis oils in preparation for the upcoming post-legalization market.  The combination of safety, pharmacokinetic and efficacy data allows Tetra to bring products to market under the proposed new regulatory framework.  Tetra Bio-Pharma is one of a few cannabinoid based companies that is committed to providing much needed clinical data for both its pharmaceutical and natural health products. 

Over the coming months Tetra Bio-Pharma will deliver its findings in a series of presentations and scientific articles that will be published in 2018 to share the clinical data of both the inhalation and oral clinical development programs with the medical community,  beginning with the July 4, 2018 International Cannabinoid Research Society Meeting in the Netherlands where Dr. Maria-Fernanda Arboleda, MD, will    present   the results   of    the    above   clinical   trial."

This is not fluff at all. The potential findings in a healthy human trial are pivotal to our marketing applications as stated above, not to mention the discoveries we may have actually made doing a clinical trial on smokeable marijuana. Any positive data they produce in testing healthy individuals they can then monetize later on by custom blending their products to cater to those same individuals. For example, possibly titrating doses based on how quickly the medication crossed the blood brain barrier. Formulating a regimen to achieve optimum blood plasma levels. The list could go on. 

This method is the same method that was done just like when Banting and Best introduced insulin for the first time. Only we are not testing the effects of insulin on the pancreas of the dog, we are testing marijuana on humans. Dr. Arboleta will produce the findings and Tetra is giving us a timeline yet again, saying that over the coming months we will be presenting more and more findings STARTING with July 4th. We are establishing credibility in the scientific world.

What happens when the scientific world takes hold of this information? They publish findings. What happens when they publish findings? Doctors gather intel. When doctors gather intel? They prescribe PPP001 or whatever drug Tetra markets condusive to the findings. This of course turns into sales, sales to profit and profit to Share Price.

I hope you sort out your predjudice towards Quebec scientists, my money is right where it needs to be.

:) Lets go TBP    

<< Previous
Bullboard Posts
Next >>